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Abstract 
Sensorimotor gating measured by prepulse inhibition (PPI) of the acoustic startle response 
(ASR) has been proposed as one of the most promising electrophysiological endophenotypes of 
schizophrenia. During the past decade, a number of publications have reported significant associations 
between genetic polymorphisms and PPI in samples of schizophrenia patients and healthy volunteers. 
However, an overall evaluation of the robustness of these results has not been published so far. 
Therefore, we performed the first meta-analysis of published and unpublished associations between 
gene polymorphisms and PPI of ASR. Unpublished associations between genetic polymorphisms and 
PPI were derived from three independent samples. In total, 120 single observations from 16 
independent samples with 2,660 study participants and 43 polymorphisms were included. After 
correction for multiple testing based on false discovery rate and considering the number of analyzed 
polymorphisms, significant associations were shown for four variants, even though none of these 
associations survived a genome-wide correction (P < 5*10-8). These results imply that PPI might be 
modulated by four genotypes – COMT rs4680 (primarily in males), GRIK3 rs1027599, TCF4 
rs9960767, and PRODH rs385440 – indicating a role of these gene variations in the development of 
early information processing deficits in schizophrenia. However, the overall impact of single genes on 
PPI is still rather small suggesting that PPI is – like the disease phenotype – highly polygenic. Future 
genome-wide analyses studies with large sample sizes will enhance our understanding on the genetic 
architecture of PPI. 
 
Keywords 
Prepulse inhibition; startle; sensorimotor gating; polymorphism; SNP; genotype; gene; mutation; 
schizophrenia; psychosis; endophenotype; intermediate phenotype; meta-analysis 
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Introduction 
Prepulse inhibition (PPI) of the acoustic startle response (ASR) is defined as a substantial 
reduction of the startle amplitude that occurs when a startling stimulus is preceded within a timeframe 
of 20-500 ms by a stimulus of lower intensity than the startling stimulus (Graham, 1975). PPI has been 
shown to occur across species ranging from mollusks and fishes to mammals including non-human 
and human primates (Burgess and Granato, 2007; Frost et al., 2003; Hoffman and Searle, 1965; Ison 
and Leonhard, 1970; Krauter et al., 1973; Linn and Javitt, 2001). Animal studies carried out 
predominantly in rodents suggested that PPI is regulated by a cortico-striato-pallido-pontine (CSPP) 
circuitry including frontal and mediotemporal regions, ventral striatum, ventral pallidum, and pontine 
regions of the brainstem (Fendt et al., 2001; Swerdlow et al., 2001). Within the CSPP circuit, several 
neurotransmitters have been demonstrated to play a major role in the mediation of PPI such as 
dopamine, noradrenaline, serotonin, acetylcholine, glutamate, and γ-aminobutyric acid (GABA) 
(Geyer et al., 2001; Koch, 1999). Consequently, PPI has been proposed as a “window” into brain 
chemistry potentially allowing the identification of neuropharmacological alterations in specific 
psychiatric disorders with PPI abnormalities (Braff, 2010). In fact, lower PPI levels have been 
reported for several neuropsychiatric disorders (Braff et al., 2001; Kohl et al., 2013; Quednow, 2008), 
but were replicated best for schizophrenia spectrum disorders (e.g., Braff et al., 1992; Cadenhead et 
al., 1993; Kumari et al., 2000; Ludewig et al., 2003; Parwani et al., 2000; Quednow et al., 2006; 
Swerdlow et al., 2014). Given that PPI shows such a robust association with schizophrenia and 
because it is heritable (Anokhin et al., 2003; Greenwood et al., 2007; 2016; Willott et al., 1994; 2003), 
reduced in unaffected relatives of schizophrenia patients (Cadenhead et al., 2000; Kumari et al., 2005), 
and already decreased in early (prodromal) stages of the disease (Quednow et al., 2008a; Ziermans et 
al., 2011; 2012), PPI was suggested as an promising candidate of an intermediate or endophenotypic 
marker in genetic studies of schizophrenia (Braff and Light, 2005; Gottesman and Gould, 2003). 
Specifically, the substantial heritability of PPI in humans – ranging from 29% to 50% across a number 
studies – suggests PPI as a favorable target for genetic analyses (Anokhin et al., 2003; Greenwood et 
al., 2007; Hasenkamp et al., 2010; Seidman et al., 2015). Additionally, it was recently shown that PPI 
revealed substantially increased heritability (47%) in 97 families multiply affected by schizophrenia 
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when compared with a 96 families, in which only a single individual was affected (2%). This finding 
further promotes the assumption that a commonality of genes underlies both schizophrenia and PPI 
(Greenwood et al., 2016). 
The endophenotype concept assumes that an endophenotypic marker is a heritable, quantifiable, 
and stable trait, which is determined by a smaller number of genes compared to the respective complex 
disease phenotype (Braff et al., 2007). Accordingly, in the last decade several research groups aimed 
to identify gene effects on the expression of PPI. The first positive findings were published in 2008, 
where associations of PPI with single nucleotide polymorphisms (SNPs) of the neuregulin-1 (NRG1, 
rs3924999) (Hong et al., 2008), catechol-O-methyltransferase (COMT, rs4680) (Roussos et al., 
2008b), dopamine D3 receptor (DRD3, rs6280) (Roussos et al., 2008a), and the serotonin-2A receptor 
(5-HT2AR, rs6311/6313) gene (Quednow et al., 2008b) have been reported from hypothesis-driven 
single association studies. Since then a number of further single association studies reported 
significant associations of PPI with numerous SNPs, which mainly have been identified as 
schizophrenia risk genes previously (for a list of studies and SNPs see Table 1 and 2, respectively). 
The only SNPs that have been replicated in at least two independent samples so far are CHRNA3 
(rs1051730) (Petrovsky et al., 2010), 5-HT2AR (rs6311/6313) (Quednow et al., 2008b; 2009), COMT 
(rs4680) (Liu et al., 2013; Quednow et al., 2009; 2010; Roussos et al., 2008b), NRG1 (rs3924999) 
(Hong et al., 2008), TCF4 (rs9960767) (Quednow et al., 2011), and DRD2 (rs1800497) (Volter et al., 
2012). However, for most of these SNPs also negative findings have been reported. Most recently, the 
first explorative genome-wide association study (GWAS) identified two non-coding loci (rs61810702 
and rs4718984) that were co-localized with expression quantitative trait loci related with the gene 
expression of nerve growth factor (NGF) and calneuron 1 (CALN1) genes. Additionally, a higher 
polygenic risk score for schizophrenia was associated with lower PPI (Roussos et al., 2016). 
The heterogeneity of these genetic results implies i) that there are probably no single genes with 
a high impact on PPI and ii) that there are likely also some false positive results considering that – 
from today’s perspective – many of the previous studies are strongly underpowered and lack 
replication samples (Button et al., 2013). One way to reduce the number of false positive (but also 
false negative) results in psychiatric genetics is the application of a meta-analysis, in which all 
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available data are included (Levinson, 2005; Lohmueller et al., 2003). Therefore, we performed a 
systematic meta-analysis of all genotype-SNP associations published so far using a weighted Z-
method approach (Stouffer et al., 1949). We additionally included three independent data sets coming 
from samples that have been published before for reporting of genotype-PPI associations but for which 
also yet unpublished genotype or GWAS data existed (Petrovsky et al., 2010; Quednow et al., 2008b; 
2009; 2010; 2011; Roussos et al., 2016). Genetic variants were included into the analysis if they were 
available in at least two independent samples. In order to control for multiple comparisons, a false 
discovery rate (FDR) method based on estimation of tail area-based FDR was applied (Strimmer, 
2008). The aim of this systematic meta-analysis was the identification of the most robust i.e., 
significant genotype-PPI associations. 
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Methods 
Eligibility criteria 
Human association studies (single associations and GWAS) with genetic variants reporting p-
values and direction of effect for PPI-genotype associations in samples of healthy controls or patients 
with schizophrenia spectrum disorders. To be included, a gene variant must have been available in at 
least two independent samples.  
 
Information sources and search strategy 
With the search term (("prepulse inhibition" OR "sensorimotor gating") AND (mutation OR 
polymorphism OR polymorphisms OR snp OR snps OR gene OR genotype) NOT (rats OR rat OR 
mice OR mouse)) NOT review[ptyp]), 63 articles have been identified initially by a MEDLINE search 
(PubMed.gov). Only studies reporting p-values of genetic effects on PPI in healthy volunteers and 
patients with schizophrenia spectrum disorders were included. Studies investigating PPI-gene 
associations in pregnant women or individuals with developmental disorders (e.g., with 22q11 
syndrome) were excluded. With this procedure, we identified 19 original articles reporting SNP-PPI 
associations (Table 1). After checking, if at least two p-values of a specific genotype-PPI and from 
independent samples are available (e.g., in two publications or in a publication and an unpublished 
data set), 120 single observations from 16 independent samples with 2,660 study participants and 43 
polymorphisms were included in the meta-analysis (Table 2). 
 
Inclusion of unpublished data 
The authors included unpublished genotype-PPI association data from three samples that have 
been published before: (1) the LOGOS sample recruited in Crete, Greece, consisting of healthy 
volunteers (max. n=686) (Roussos et al., 2016), (2) a sample of healthy volunteers (max. n=100) from 
London, UK (Petrovsky et al., 2010; Quednow et al., 2009; 2011), and (3) a sample of patients with 
schizophrenia spectrum disorders (max. n=107) from Bonn, Germany (Petrovsky et al., 2010; 
Quednow et al., 2008b; 2010; 2011). P-values of yet unpublished genotype-PPI associations have been 
calculated using the same statistical approach as previously reported, e.g., using the same covariates 
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such as sex, smoking status, and antipsychotic medication (London and Bonn samples: Quednow et 
al., 2011). The final studies, cohorts and number of samples per study included in the meta-analysis is 
shown in Table 1 and 2. 
 
Statistical Analysis 
We sum the association evidence across studies using a weighted Z-method approach where 
every study is weighted by the effective sample size (Stouffer et al., 1949). Briefly, in each study, we 
convert Pi P-values into Zi signed Z-scores based on the Δi direction of effect using the following 
equation: 
ܼ௜ ൌ 	߶ିଵ 	ቀ௉೔ଶ ቁ ∗ 	ݏ݅݃݊ሺ∆௜ሻ. 
We then estimate overall Z score by summing Z-scores for each genetic polymorphism using 
weights proportional to the square-root of the sample size for each study:  
ܼ ൌ 	 ∑ ௓೔௪೔೔
ට∑ ௪೔మ೔
, 
where ݓ௜ ൌ 	ඥ ௜ܰ and Ni is the sample size of study i. Finally, the overall Z score is converted 
back to overall P-value for a given genotype based on: 
ܲ ൌ 2Φሺ| െ ܼ|ሻ. 
For multiple testing correction, we applied FDR at combined P-values estimated based on 
fdrTool in R (Strimmer, 2008). The Cohen’s d effect sizes for the strengths of association were 
estimated from Z-values according to Rosenthal (1984). For estimation of effect sizes in schizophrenia 
GWAS study we used the average odds ratio of 1.1 across all genome-wide significant SNPs and 
estimated Cohen’s d based on:  
݀ ൌ 	ܮ݋ܱ݃݀݀ݏܴܽݐ݅݋	ݔ	 √3ߨ  
As sex effects are well-documented for the rs4680 COMT SNP (Tunbridge and Harrison, 2011), 
and as strong sex differences in rs4680 COMT effects on PPI were recently reported in a non-trivial 
sample of healthy subjects (Swerdlow et al., 2017), we additionally analyzed sex effects for this SNP 
only. Based on the existing studies, we are well powered to study the COMT association in males only 
as the majority of the included samples with known gender (92% or 870 out of 943) were males.
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Results 
In this study, we examined the associations of SNPs and PPI of ASR. We evaluated a total of 43 
SNP-PPI associations, while for each SNP two to six samples were available (mean 2.8, standard 
deviation 1.1, median 2.0 samples). Statistical significance was defined as an FDR-adjusted p-value of 
0.05 or smaller. At this threshold, four index SNPs were significant. The strongest association was 
between COMT rs4680 and PPI (P = 5.5*10-5, FDR = 0.002, Cohen’s d = 0.28) in male samples only 
(Table 2). The other three loci with significant association with PPI were: GRIK3 rs1027599 (P = 
0.004, FDR = 0.045, Cohen’s d = 0.19), TCF4 rs9960767 (P = 0.006, FDR = 0.050, Cohen’s d = 0.19) 
and PRODH rs385440 (P = 0.006, FDR = 0.050, Cohen’s d = 0.27). As expected, the detected 
Cohen’s d effect sizes are small according to the definition of Cohen (1988) and none of these 
associations survived a genome-wide correction (P < 5*10-8). Notably, we also found a significant 
effect for COMT rs4680 in both males and females, but with smaller effect size that did not survive 
multiple testing corrections (P = 0.01, FDR = 0.057, Cohen’s d = 0.15), indicating a putative gender-
specific effect of COMT on PPI.  
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Discussion 
The aim of this meta-analysis was the identification of robust associations between gene 
polymorphisms and PPI of the ASR. Given that PPI was repeatedly proposed as an endophenotype of 
schizophrenia (Braff et al., 2007), this investigation might elucidate which genes may robustly 
contribute to the low PPI levels of schizophrenia patients and presumably to the disease itself. We thus 
analyzed published and unpublished data resulting in the inclusion of 120 single observations from 16 
independent samples with 2,660 study participants and 43 polymorphisms. After multiple testing 
corrections based on an FDR approach, four polymorphisms were significantly associated with PPI. In 
males, the COMT rs4680 (Val158Met) polymorphism showed the strongest association with PPI (P = 
5.5*10-5, FDR = 0.002, Cohen’s d = 0.28), while the COMT gene effect was barely not significant (P = 
0.01, FDR = 0.057, Cohen’s d = 0.15) in the mixed-gender sample. Carriers of the COMT rs4680 G 
(valine) allele showed lower PPI levels than carriers of the A (methionine) allele. Moreover, GRIK3 
rs1027599 (P = 0.004, FDR = 0.045, Cohen’s d = 0.19), TCF4 rs9960767 (P = 0.006, FDR = 0.050, 
Cohen’s d = 0.19), and PRODH rs385440 (P = 0.006, FDR = 0.050, Cohen’s d = 0.27) showed 
significant association with PPI. Regarding GRIK3 rs1027599, the T allele carriers showed lower PPI, 
while the same was true for TCF4 rs9960767 C and PRODH rs385440 A allele carriers. In fact, when 
the widely accepted threshold for genome-wide multiple corrections (P < 5*10-8) is applied, none of 
the results is powerful enough to survive. However, it has to be taken into account that the power of 
this meta-analysis (sample size range: N=436 to 1224) was much lower, e.g., compared to previously 
published mega-analyses in schizophrenia genetics, including ten thousands of participants (Ripke et 
al., 2013; Steinberg et al., 2011). Nevertheless, the effect sizes of the significant SNPs in the present 
meta-analysis are small (Cohen’s d = 0.19 to 0.28) in the sense of Cohen’s definition (Cohen, 1988) 
but relatively strong considering the strengths of genetic associations commonly shown in meta-
analysis of GWAS in schizophrenia (Cohen’s d = 0.05 based on Schizophrenia Working Group of the 
Psychiatric Genomics, 2014). 
 
The COMT gene effect on PPI is highly plausible as the COMT enzyme is involved in in the 
metabolic inactivation of dopamine and norepinephrine in regions with a low density of dopamine and 
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noradrenaline transporters specifically in the frontal cortex (Rivett et al., 1982). The rs4680 
polymorphism leads to an amino acid substitution of methionine for valine changing the metabolic rate 
of the enzyme. Consequently, compared to methionine homozygotes, valine homozygotes have a 3 to 
4-fold stronger COMT enzyme activity and, thus, an increased catabolism of catecholamines in the 
frontal cortex (Lachman et al., 1996). Animal and human studies suggest that PPI is critically 
modulated by dopamine and noradrenaline neurotransmission at several stages of the CSPP circuit 
(Geyer et al., 2001; Swerdlow et al., 2001). Moreover, COMT messenger RNA is highly expressed in 
the prefrontal cortex and the hippocampus and less in the striatum, the ventral tegmental area, or the 
substantia nigra (Tunbridge et al., 2006). Considering that these structures are participating in the 
CSPP circuit, it is likely that the COMT polymorphism influences PPI at the prefrontal or hippocampal 
level (Swerdlow et al. 2001; Quednow et al, 2010). Specifically, lower prefrontal dopamine 
concentrations probably contribute to reduced PPI levels in valine allele carriers as is was shown that 
reduced dopamine activity in the prefrontal cortex goes along with a disruption of PPI (Bubser and 
Koch, 1994; Ellenbroek et al., 1996; Zavitsanou et al., 1999). In addition, drug-induced inhibition of 
the COMT enzyme with tolcapone leads to PPI enhancement only in the COMT Val carriers (Bitsios 
and Roussos, 2011; Giakoumaki et al., 2008; Roussos et al., 2009b). In line with these human data, it 
was shown that the effects of COMT inhibition by tolcapone on amphetamine-modified PPI were 
categorically different in rat strains exhibiting low vs. high levels Comt expression in the forebrain 
(Swerdlow et al., 2013). Moreover, genetic associations between COMT and psychiatric phenotypes 
frequently display sex differences (Tunbridge and Harrison, 2011). Accordingly, COMT rs4680 
genotype effects on PPI have been demonstrated particularly in males, while the gene effects were 
absent, less strong, or even reversed in females (Montag et al., 2008; Quednow et al., 2009; 2010; 
Roussos et al., 2008b; Swerdlow et al., 2017). Finally, COMT rs4680 has been proposed to be a risk 
gene for schizophrenia for a long time but recent meta-analytical results are conflicting (Gonzalez-
Castro et al., 2016; Taylor, 2017). Again, associations between COMT rs4680 and schizophrenia or 
schizotypy have been demonstrated primarily in males but not females (for reviews see Tunbridge and 
Harrison, 2011). Thus, the sex-specific effect of the COMT rs4680 on PPI shown here is in agreement 
with a variety of previous findings.  
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The GRIK3 gene encodes the glutamate ionotropic receptor kainate type subunit 3, which is one 
of three principal subunits (GRIK1-3) of the tetrameric kainate/AMPA receptors. Two further 
auxiliary subunits of these receptors exist (GRIK4-5) (Fernandez et al 2009, Neuron). GRIK3-
containing receptors differ from other kainate/AMPA receptors as they can only be activated by fast 
and strong glutamate releases. Moreover, they have some special electrophysiological properties 
suggesting that GRIK3-containing receptors have specialized presynaptic functions (Perrais et al., 
2009). Decreased expression of GRIK3 in the prefrontal cortex and hippocampus of schizophrenia 
patients have been shown (Hu et al., 2015): While there are no published positive associations of the 
GRIK3 rs1027599 SNP with psychiatric disorders so far, other GRIK3 SNPs have been associated 
with schizophrenia (Begni et al., 2002; Kilic et al., 2010) and major depression (Schiffer and 
Heinemann, 2007), previously. Moreover, sporadic deletion in chromosome 1p34.3 involving GRIK3 
was reported for a girl with developmental delay (Takenouchi et al., 2014). Interestingly, in a recent 
twin study, a GRIK3 gene set was associated with overall startle responses (Vaidyanathan et al., 2014), 
raising the question if the association with PPI shown here is rather an epiphenomenon of changes in 
startle reactivity (Csomor et al., 2008). Moreover, the kainate antagonist LY382884 reduced both 
exaggerated ASR and PPI deficits observed in mice with genetically reduced NMDA receptor 
expression (Duncan et al., 2010). However, these results might be explained by the changes in ASR 
again, as strongly elevated startle responses can result in low PPI levels also in mice (Csomor et al., 
2008).  
 
TCF4 belongs to the superfamily of basic Helix-Loop-Helix (bHLH) transcription factors that 
can act as a transcriptional repressor or activator in a context specific fashion. It can be considered as 
an integrator (‘hub’) of several bHLH networks controlling critical steps of various developmental and 
plasticity related transcriptional programs in neurons (Quednow et al., 2014). Haploinsufficiency of 
the TCF4 gene causes the Pitt-Hopkins syndrome – a severe neurodevelopmental disease characterized 
by mental retardation, microcephaly, epilepsy, facial dysmorphisms, and intermittent hyperventilation 
–, suggesting that TCF4 is critical for the development of the mammalian nervous system (de Pontual 
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et al., 2009; Zweier et al., 2007). Three large but also partially overlapping meta-analyses of GWAS 
consistently identified that common TCF4 polymorphisms are associated with the risk of 
schizophrenia (Schizophrenia Psychiatric Genome-Wide Association Study, 2011; Stefansson et al., 
2009; Steinberg et al., 2011). In these analyses, two SNPs at the intron located between the internal 
exon 4 and internal exon 5 of human TCF4 gene on chromosome 18q21.2 (rs9960767, rs17512836) 
and an intragenic SNP near the TCF4 gene (rs4309482) have shown the strongest association with the 
disease (Schizophrenia Psychiatric Genome-Wide Association Study, 2011; Stefansson et al., 2009; 
Steinberg et al., 2011). Several subsequent studies replicated schizophrenia-TCF4 gene associations in 
independent samples: (1) Two studies in Han Chinese (in which the rs9960767 SNP is not 
polymorphic) identified TCF4 rs2958182 (Li et al., 2010) as well as rs9320010, rs7235757, and 
rs1452787 (Li et al., 2016) to be associated with schizophrenia. (2) In a discovery sample from Ireland 
and a replication sample including non-overlapping samples from the Psychiatric GWAS Consortium 
(PGC), two intronic TCF4 SNPs (again rs9960767 and rs17594526) passed the genome-wide 
significance threshold of p<5*10-8 (Irish Schizophrenia Genomics and the Wellcome Trust Case 
Control, 2012). (3) In a recent family-based linkage meta-analysis a further TCF4 SNP was identified 
(rs1261117) as linked to schizophrenia (Aberg et al., 2013). These results have contributed to the view 
that TCF4 SNPs belong to the best-replicated schizophrenia susceptibility genes. A potential 
disturbance of TCF4 function in schizophrenia would be in line with the assumption that 
schizophrenia is a neurodevelopmental disorder (Quednow et al., 2014); however, the exact functional 
impact of the discussed TCF4 SNPs has still to be elucidated. Finally, transgenic mice moderately 
overexpressing TCf4 in the brain as well as TCf4 haploinsufficient mice both display profound 
reductions in PPI (Brzozka et al., 2010; Kennedy et al., 2016). Beyond PPI, TCF4 SNPS including 
rs9960767 have been shown to be associated with another proposed endophenotype of schizophrenia: 
P50 suppression also called “sensory gating”; however, this association was only present in smoking 
individuals but not in never-smokers (Quednow et al., 2012). Taken together, the significant 
association of TCF4 rs9960767 and PPI in human cohorts reported here is neurobiologically and 
pathophysiologically plausible as well.  
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PRODH encodes the enzyme proline oxidase, which is involved, among other functions, in the 
conversion of proline to D-1-pyrroline-5-carboxylate (P5C) in mitochondria. P5C is subsequently 
converted to glutamate or GABA, two neurotransmitters critically implicated in the pathophysiology 
of schizophrenia (Roussos et al., 2009a). Together with COMT, PRODH is located at 22q11 and, thus, 
both genes belong to the ~30 genes affected by the 22q11 deletion syndrome (Velo-Cardio-Facial or 
DiGeorge syndrome). Individuals with a 22q11 deletion syndrome show a strongly elevated risk for 
schizophrenia symptoms (Prasad et al., 2008) as well as reductions of PPI (Sobin et al., 2005a, b). In 
addition, rodent models of the 22q11 syndrome are associated with deficits in PPI (Diamantopoulou et 
al., 2017; Didriksen et al., 2017; Gogos et al., 1999). Previous studies suggested a possible role of the 
PRODH gene variations, in the pathogenesis of schizophrenia. Specifically, PRODH haplotypes 
consisting of rs372055 (1945T>C), rs450046 (1766A>G), and rs385440 (1852G>A) SNPs were 
significantly associated with schizophrenia, indicating that the alleles 1945C, 1766G, and 1852A are 
overtransmitted in schizophrenia patients (Li et al., 2004; Liu et al., 2002). The haplotypes, which 
included rs385440, is associated with PRODH hyperactivity potentially resulting in reduced proline 
levels and increased P5C/Glu availability in the central nervous system (Phang et al., 2008) and these 
changes might induce changes in the modulation of PPI (Roussos et al., 2009a). As both COMT and 
PRODH SNPs seem to have an impact on PPI and given that these genes are within 22q11 locus, 
further studies should investigate gene-gene interactions of both variants with regard to PPI. 
 
Limitations of our meta-analysis include the small number of included studies and sample sizes 
making the estimates of effect sizes less reliable. Moreover, for most of the SNPs only two 
independent samples were available. It should be noticed, that the PRODH effect on PPI was indeed 
similarly strong as the COMT effect in males but that the PRODH sample size was nevertheless the 
lowest amongst all analyzed SNPs. Thus, the PRODH effect is likely less reliable than the COMT 
effect. Moreover, similar as for PRODH, the GRIK effect was calculated from only two studies, while 
three studies were included for TCF4 and four regarding COMT (in males, and six for COMT 
including females). Consequently, the GRIK effects might also be less robust compared to TCF4 and 
COMT (in males). Finally, we used a weighted Z-method approach using reported p-values to 
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calculate the meta-analysis and consequently, statistical differences between studies (e.g., regarding 
the inclusion of different sets of covariates) have not been considered. Accordingly, as we did not use 
the original data sets of previously published work we were not able to adjust the results for the 
common confounding factors affecting PPI, such as gender and menstrual cycle, smoking, startle 
magnitude, as well as medication (Quednow, 2008). Particularly in patient samples, PPI-gene 
associations could have been masked by the potential PPI-enhancing impact of antipsychotic 
medication (Quednow et al., 2006; 2008a). However, several previous studies have controlled for such 
confounding factors and reported adjusted p-values, but not all. The additional analyses of so far 
unpublished data from patients with schizophrenia spectrum disorders reported in the present paper in 
fact considered smoking, sex, and antipsychotic medication status as covariates and only the adjusted 
p-values were used for the meta-analysis. Nevertheless, the overall strength of the gene effects might 
have been biased by confounding factors such as antipsychotic medication. Another limitation is that 
the included studies employed a variety of different PPI setups. Given that it has not been investigated 
systematically yet, which PPI parameters (e.g., prepulse and pulse intensities, stimulus-onset 
asynchrony, number of stimuli, intertrial intervals) might provide an optimal signal-to-noise ratio with 
regard to gene effects (or if genes might specifically influence PPI at various conditions), it remains 
unclear how the heterogeneity of PPI setups used in the included studies might have affected our 
results. 
 
Beyond PPI, several further electrophysiological “gating” or filtering” paradigms have been 
proposed as potential endophenotypes and clinical biomarkers of schizophrenia, such as P50 
suppression, P300 and P3a, and mismatch negativity (MMN) (Light and Swerdlow, 2015). Many 
studies have investigated the associations between polymorphisms and these electroencephalographic 
measures but no meta-analysis has been performed for any of these markers yet (Owens et al., 2016). 
Specifically, the MMN and the P3a event related potential component might be highly promising 
targets for future endophenotype-related genetic meta-analyses given that both are strongly, robustly, 
and stably affected in schizophrenia patients and both show considerable heritability (Light and 
Swerdlow, 2015; Light et al., 2015). However, a recent well-powered study demonstrated significant 
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difficulty in the identification of genetic associations between 108 schizophrenia risk loci, a polygenic 
risk score for schizophrenia, and 17 electrophysiological schizophrenia endophenotypes, challenging 
the endophenotype concept (Liu et al., 2017) – albeit neither PPI, MMN, nor P3a (but P300) have 
been included in this analysis. Thus, future studies have to reveal if these most promising 
endophenotype candidates are more useful to decompose the genetic basis of schizophrenia or if they 
have at least a clinical relevance (Light and Swerdlow, 2015). 
 
Taken together, the present meta-analysis revealed that four SNPs located on genes that have 
been associated with schizophrenia previously, are robustly correlated with the expression of PPI in 
humans as well. These associations are neurobiologically plausible as the respective gene products 
have been shown to be involved in the CSPP circuit processing PPI (Geyer et al., 2001; Koch, 1999; 
Swerdlow et al., 2001). Although the effect sizes of the gene effects on PPI are relatively strong (at 
least when compared to the extremely weak gene effects shown in meta-analysis of GWAS in 
schizophrenia) none of the results would have survived a strict genome-wide correction of the alpha-
level. This indicates that PPI – like schizophrenia itself – is highly polygenic. Thus, the question that 
still has to be answered in the future is whether the hitherto proposed schizophrenia endophenotypes 
are in fact less polygenic as the complex disease phenotype, so that endophenotypes can be used to 
predict the risk for schizophrenia or if they can be used to discover new neurobiological treatment 
targets. 
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Tables 
 
Table 1. Summary list of published and unpublished studies included in meta-analysis.  HC = healthy controls, SCZ = patients with schizophrenia. 
Reference Sample (location) Sample number Analyzed N 
(Brauer et al., 2009) HC (Giessen) 1 81 
(Greenwood et al., 2012) SCZ (San Diego) 2 219 
(Hong et al., 2008) HC (Maryland) 3 63 
SCZ (Maryland) 4 113 
(Hokyo et al., 2010) HC (Osaka) 5 71 
SCZ (Osaka) 6 81 
(Liu et al., 2013) SCZ (Guangdong) 7 140 
(Montag et al., 2008) HC (Bonn-Montag) 8 96 
(Petrovsky et al., 2010) HC (London) 9 96 
SCZ (Bonn) 10 68 
(Petrovsky et al., 2013) HC (Bonn) 11 63 
(Quednow, Ettinger, Kumari, unpublished data) HC (London) 9 100 
(Quednow and Wagner, unpublished data) SCZ (Bonn) 10 107 
(Quednow et al., 2008b) SCZ (Bonn) 10 68 
(Quednow et al., 2009) HC (London) 9 99 
(Quednow et al., 2010) SCZ (Bonn) 10 71 
(Quednow et al., 2011) HC (London) 9 98 
SCZ (Bonn) 10 105 
(Roussos et al., 2008a) HC (Crete) 12 101 
(Roussos et al., 2008b) HC (Crete) 12 93 
(Roussos et al., 2009a) HC (Crete) 12 217 
(Roussos et al., 2011) HC (LOGOS) 13 445 
(Roussos et al., 2016) HC (LOGOS GWAS) 14 686 
(Shi et al., 2016) SCZ (Beijing) 15 77 
(Volter et al., 2012) HC (London) 9 96 
HC (Munich) 16 101 
Varying sample sizes among single samples (e.g., sample nr. 10: range n=68-107) are explained by different schizophrenia spectrum 
diagnosis included or because genotype was only available in a subsample (e.g., due to genotyping failures). 
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Table 2. Combined and Z-scores and P-values across genotypes where data were available at least in two independent samples. The signed Z-score indicates 
the direction of association among genotype and PPI. Negative Z-scores indicate decreased PPI in the reference compared to the alternative allele; Positive Z-
scores indicate increased PPI in the reference compared to the alternative allele. Results with false discovery rate (FDR) ≤ 0.05 are in bold. 
 
 
SNP Gene Number of studies Total sample Reference allele Combined Z-score Cohen’s d Combined P-value FDR 
rs4680 (only males) COMT 4 870 A 4.03 0.28 5.51E-05 0.002 
rs1027599 GRIK3 2 905 C 2.87 0.19 0.004 0.045 
rs9960767 TCF4 3 889 C -2.77 0.19 0.006 0.050 
rs385440 PRODH 2 436 A -2.75 0.27 0.006 0.050 
rs533337 GRIK3 2 905 A 2.64 0.18 0.008 0.055 
rs4680 COMT 6 1,179 A 2.58 0.15 0.010 0.057 
rs13101891 GRID2 2 905 G -2.41 0.16 0.016 0.067 
rs1800497 DRD2 5 1,047 A2 -2.40 0.15 0.017 0.067 
rs4782262 GRIN2A 2 905 C 2.36 0.16 0.018 0.069 
rs876848 GAD2 2 905 T -2.27 0.15 0.023 0.074 
rs1044396 CHRNA4 3 863 T -2.26 0.15 0.024 0.075 
rs1923292 SLC1A2 2 905 G -2.15 0.14 0.032 0.097 
rs40184 SLC6A3 3 998 A 2.14 0.14 0.033 0.100 
rs4852550 CTNNA2 2 905 T -2.06 0.14 0.039 0.118 
rs308787 GRM5 2 905 G 2.04 0.14 0.041 0.122 
rs3924999 NRG1 5 1,180 A -2.03 0.12 0.042 0.126 
rs8068673 PAFAH1B1 2 905 C 2.01 0.13 0.045 0.132 
rs6277 DRD2 4 905 G -2.00 0.13 0.046 0.135 
rs701567 DAOA 2 905 G 1.91 0.13 0.057 0.162 
rs1587526 GRIK3 2 905 A 1.90 0.13 0.057 0.163 
rs894829 CTNNA2 2 905 G -1.89 0.13 0.059 0.167 
rs1266475 PAFAH1B1 2 905 C 1.88 0.13 0.060 0.169 
rs6311 5HT2AR 3 851 A 1.87 0.13 0.062 0.173 
rs1051730 CHRNA3 4 902 T -1.79 0.12 0.074 0.200 
rs6994992 NRG1 3 1,224 T -1.79 0.10 0.074 0.202 
  26
rs10095556 NRG1 2 905 G 1.72 0.11 0.086 0.226 
rs12685902 GRIN3A 2 905 C -1.68 0.11 0.094 0.242 
rs11782671 NRG1 2 905 T 1.66 0.11 0.098 0.250 
rs9297186 NRG1 2 905 A 1.59 0.11 0.111 0.275 
rs778294 DAOA 3 1,003 A 1.36 0.09 0.175 0.373 
rs6280 DRD3 4 1,070 G -1.34 0.08 0.181 0.381 
rs8081803 PAFAH1B1 2 905 C 1.21 0.08 0.225 0.433 
rs6313 5HT2AR 5 1,151 T 1.12 0.07 0.265 0.474 
rs2619539 DTNBP1 4 1,105 C -0.99 0.06 0.324 0.524 
rs2008626 NRG1 2 905 C -0.97 0.06 0.334 0.532 
rs1368909 CTNNA2 2 905 C -0.93 0.06 0.350 0.544 
rs165599 COMT 3 928 G -0.81 0.05 0.417 0.586 
rs3814614 GRID1 2 905 C 0.79 0.05 0.431 0.595 
rs7555221 GRIK3 2 905 C -0.56 0.04 0.578 0.663 
rs4648317 DRD2 4 948 G -0.52 0.03 0.601 0.672 
rs2619528 DTNBP1 4 941 G 0.49 0.03 0.625 0.680 
rs1486009 DRD3 2 905 G -0.48 0.03 0.634 0.683 
rs4584372 NOS1AP 2 905 C -0.34 0.02 0.736 0.715 
rs1011313 DTNBP1 4 1,108 A 0.08 0.01 0.933 0.760 
 
